Skip to main
LNTH
LNTH logo

Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings (LNTH) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Lantheus Holdings Inc demonstrates a positive outlook driven by the anticipated growth of its POSLUMA product, which is projected to increase its U.S. revenue and unit share significantly by the first quarter of 2025. Additionally, the new Pylarify formulary, expected to enhance batch size by approximately 50%, alongside three years of therapy protocol eligibility, is likely to revitalize Pylarify's growth trajectory beginning in the fourth quarter of 2026. Overall, the combination of product advancements and strategic developments positions Lantheus for promising financial performance in the coming years.

Bears say

Lantheus Holdings Inc has experienced a decline in its revenue from Pylarify, generating $260 million, which reflects an 8% year-over-year decrease and falls approximately $14 million short of consensus expectations. The company's two-year growth profile has now positioned it below its profitable SMID MedTech peers, compounded by a reduction in Pylarify growth forecasts for 2025-2026. Additionally, weak unit growth of only 2% year-over-year, combined with a significant 10% price headwind during the quarter, underscores challenges in maintaining revenue momentum.

Lantheus Holdings (LNTH) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lantheus Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lantheus Holdings (LNTH) Forecast

Analysts have given Lantheus Holdings (LNTH) a Buy based on their latest research and market trends.

According to 6 analysts, Lantheus Holdings (LNTH) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $74.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $74.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lantheus Holdings (LNTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.